| Literature DB >> 33519806 |
Chao Ma1,2, Jerry B Hunt2,3, Maj-Linda B Selenica3,4, Awa Sanneh3, Leslie A Sandusky-Beltran3, Mallory Watler3, Rana Daas3, Andrii Kovalenko3, Huimin Liang2,3, Devon Placides3, Chuanhai Cao3, Xiaoyang Lin3, Michael B Orr5, Bei Zhang5,6, John C Gensel5, David J Feola7, Marcia N Gordon8, Dave Morgan8, Paula C Bickford1,9,10, Daniel C Lee2,3.
Abstract
Alzheimer's disease (AD) includes several hallmarks comprised of amyloid-β (Aβ) deposition, tau neuropathology, inflammation, and memory impairment. Brain metabolism becomes uncoupled due to aging and other AD risk factors, which ultimately lead to impaired protein clearance and aggregation. Increasing evidence indicates a role of arginine metabolism in AD, where arginases are key enzymes in neurons and glia capable of depleting arginine and producing ornithine and polyamines. However, currently, it remains unknown if the reduction of arginase 1 (Arg1) in myeloid cell impacts amyloidosis. Herein, we produced haploinsufficiency of Arg1 by the hemizygous deletion in myeloid cells using Arg1fl/fl and LysMcreTg/+ mice crossed with APP Tg2576 mice. Our data indicated that Arg1 haploinsufficiency promoted Aβ deposition, exacerbated some behavioral impairment, and decreased components of Ragulator-Rag complex involved in mechanistic target of rapamycin complex 1 (mTORC1) signaling and autophagy. Additionally, Arg1 repression and arginine supplementation both impaired microglial phagocytosis in vitro. These data suggest that proper function of Arg1 and arginine metabolism in myeloid cells remains essential to restrict amyloidosis.Entities:
Keywords: Alzheimer’s disease; Tg2576; arginine metabolism; cognition; macrophage; microglia; neuroinflammation; phagocytosis
Year: 2021 PMID: 33519806 PMCID: PMC7840571 DOI: 10.3389/fimmu.2020.582998
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561